Copyright: ©Author(s) 2026.
World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 118130
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.118130
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.118130
Figure 1 Temporal trends of obstructive sleep apnea in metabolic dysfunction-associated fatty liver disease (2010-2024).
A: Incidence. Annual incidence proportion of obstructive sleep apnea (OSA) among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) from 2010 to 2024. The purple line represents the observed incidence (%) for each year. The black dashed line represents the Sen’s slope estimate, demonstrating the monotonic upward trend identified by the Mann-Kendall test; B: Prevalence. Annual prevalence of OSA among individuals with MASLD from 2010 to 2024. The purple line displays observed prevalence (%) each year while the black dashed line shows the Sen’s slope trend line based on non-parametric trend estimation. Statistical significance of temporal trends was evaluated using the Mann–Kendall test. OSA: Obstructive sleep apnea; MASLD: Metabolic dysfunction-associated steatotic liver disease.
Figure 2 Kaplan-Meier curves comparing obstructive sleep apnea-free probability between metabolic dysfunction–associated steatotic liver disease and non-metabolic dysfunction-associated steatotic liver disease populations.
Kaplan–Meier survival curves demonstrating obstructive sleep apnea (OSA)-free probability over time among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared with a propensity-matched cohort without MASLD. Vertical dashed lines indicate key timepoints at which OSA-free probabilities diverge: 189 days for the MASLD cohort and 358 days for the non-MASLD cohort. The non-MASLD cohort showed consistently higher OSA-free probability across the follow-up period. The hazard ratio for the comparison was 1.152 (95%CI: 1.130-1.174) with a log-rank P < 0.0001, indicating a statistically significant difference between groups. OSA: Obstructive sleep apnea; MASLD: Metabolic dysfunction-associated steatotic liver disease.
- Citation: Chowdhary R, Song GQ, Goyal MK, Vuthaluru AR, Arora K, Chowdhary R, Patel M, Batta A, Koo TH, Sunkesula V, Goyal R, Goyal O. Metabolic dysfunction–associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes. World J Gastrointest Pharmacol Ther 2026; 17(2): 118130
- URL: https://www.wjgnet.com/2150-5349/full/v17/i2/118130.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.118130